Profile data is unavailable for this security.
About the company
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
- Revenue in USD (TTM)2.31m
- Net income in USD-193.58m
- Incorporated1995
- Employees285.00
- LocationLexicon Pharmaceuticals Inc8800 TECHNOLOGY FOREST PLACE8800 TECHNOLOGY FOREST PLACETHE WOODLANDS 77381United StatesUSA
- Phone+1 (281) 863-3000
- Fax+1 (281) 863-8088
- Websitehttps://www.lexpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anika Therapeutics Inc | 166.66m | -82.67m | 409.12m | 357.00 | -- | 1.91 | -- | 2.45 | -5.64 | -5.64 | 11.37 | 14.48 | 0.5378 | 1.48 | 4.72 | 466,840.30 | -26.68 | -5.41 | -29.48 | -5.87 | 61.85 | 60.70 | -49.60 | -12.60 | 3.76 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
Revance Therapeutics Inc | 234.04m | -323.99m | 411.65m | 534.00 | -- | -- | -- | 1.76 | -3.81 | -3.81 | 2.77 | -1.72 | 0.4414 | 2.33 | 12.00 | -- | -61.11 | -55.55 | -72.36 | -63.20 | 68.23 | -- | -138.43 | -304.96 | 3.29 | -36.36 | 1.54 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
iTeos Therapeutics Inc | 12.60m | -112.64m | 419.36m | 157.00 | -- | 0.7265 | -- | 33.30 | -3.15 | -3.15 | 0.3522 | 16.05 | 0.0177 | -- | 2.82 | 80,222.93 | -15.84 | 5.84 | -16.81 | 7.02 | -- | -- | -894.35 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
OraSure Technologies, Inc. | 405.47m | 53.66m | 420.04m | 638.00 | 7.62 | 0.9373 | 5.63 | 1.04 | 0.7204 | 0.7204 | 5.47 | 5.86 | 0.8748 | 3.15 | 7.31 | 635,536.10 | 11.58 | 0.7238 | 13.11 | 0.8212 | 44.25 | 46.94 | 13.23 | 1.13 | 8.57 | -- | 0.0018 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
Lenz Therapeutics Inc | 0.00 | -124.65m | 420.30m | 6.00 | -- | 0.743 | -- | -- | -15.35 | -15.35 | 0.00 | 22.15 | 0.00 | -- | -- | 0.00 | -48.85 | -- | -50.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
Lexeo Therapeutics Inc | 0.00 | -66.39m | 420.71m | 58.00 | -- | 3.00 | -- | -- | -2.69 | -2.69 | 0.00 | 4.26 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0153 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
Cibus Inc | 1.82m | -267.63m | 422.50m | 183.00 | -- | 1.20 | -- | 232.52 | -22.63 | -22.63 | 0.1769 | 14.27 | 0.0064 | -- | -- | 9,928.96 | -119.13 | -86.28 | -135.32 | -96.45 | 2.31 | -- | -18,582.22 | -792.07 | -- | -3.70 | 0.0049 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
Mersana Therapeutics Inc | 36.86m | -171.67m | 423.37m | 123.00 | -- | 11.32 | -- | 11.49 | -1.50 | -1.50 | 0.3175 | 0.3057 | 0.1315 | -- | 2.46 | 299,634.20 | -61.27 | -61.68 | -84.73 | -81.35 | -- | -- | -465.80 | -622.19 | -- | -- | 0.408 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
Replimune Group Inc | 0.00 | -209.96m | 426.65m | 284.00 | -- | 1.01 | -- | -- | -3.16 | -3.16 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -34.66 | -26.12 | -36.63 | -27.31 | -- | -- | -- | -- | -- | -- | 0.1436 | -- | -- | -- | -47.65 | -- | 75.59 | -- |
Lexicon Pharmaceuticals Inc | 2.31m | -193.58m | 428.45m | 285.00 | -- | 1.48 | -- | 185.40 | -0.8257 | -0.8257 | 0.0098 | 1.17 | 0.008 | -- | 2.59 | 8,108.77 | -66.76 | -24.41 | -72.21 | -29.01 | 94.98 | 98.49 | -8,376.55 | -84.92 | 15.56 | -11.46 | 0.2569 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
ACELYRIN Inc | 0.00 | -381.64m | 430.27m | 130.00 | -- | 0.6486 | -- | -- | -10.84 | -10.84 | 0.00 | 6.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
Tscan Therapeutics Inc | 21.05m | -89.22m | 430.59m | 154.00 | -- | 2.71 | -- | 20.46 | -2.49 | -2.49 | 0.4421 | 3.15 | 0.0893 | -- | -- | 136,681.80 | -37.87 | -- | -42.07 | -- | -- | -- | -423.86 | -- | -- | -- | 0.1661 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
Entrada Therapeutics Inc | 129.01m | -6.69m | 442.19m | 159.00 | -- | 1.82 | -- | 3.43 | -0.2543 | -0.2543 | 3.86 | 7.25 | 0.3578 | -- | -- | 811,402.50 | -1.85 | -- | -2.47 | -- | -- | -- | -5.18 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
Adaptive Biotechnologies Corp | 170.28m | -225.25m | 443.58m | 709.00 | -- | 1.42 | -- | 2.61 | -1.56 | -1.56 | 1.18 | 2.13 | 0.2244 | 5.23 | 4.36 | 240,163.60 | -29.69 | -19.69 | -34.13 | -22.06 | 55.63 | 67.18 | -132.32 | -122.27 | 4.50 | -- | 0.00 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
Biomea Fusion Inc | 0.00 | -127.27m | 444.71m | 103.00 | -- | -- | -- | -- | -3.57 | -3.57 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -43.29 | -- | -- | -- |
Annexon Inc | 0.00 | -134.24m | 444.77m | 71.00 | -- | 1.53 | -- | -- | -1.78 | -1.78 | 0.00 | 3.20 | 0.00 | -- | -- | 0.00 | -46.07 | -44.06 | -49.49 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
Holder | Shares | % Held |
---|---|---|
Invus Public Equities Advisors LLCas of 28 Apr 2024 | 117.55m | 47.74% |
BVF Partners LPas of 31 Dec 2023 | 24.44m | 9.92% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 6.34m | 2.57% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 5.85m | 2.38% |
JPMorgan Investment Management, Inc.as of 31 Dec 2023 | 2.72m | 1.11% |
Geode Capital Management LLCas of 31 Dec 2023 | 2.35m | 0.95% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.28m | 0.93% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.89m | 0.77% |
Columbia Management Investment Advisers LLCas of 31 Dec 2023 | 1.89m | 0.77% |
Pinnacle Associates Ltd.as of 31 Mar 2024 | 1.75m | 0.71% |